FDA warned Centura Pharmaceuticals that its BLT 1-2-3 Cream, a mixed numbing product for cosmetic procedures, is an unapproved new drug.
What happened
In April 2024 FDA reviewed the company's product labeling and its websites (centurapharma.com and centurabltcream.com), where BLT 1-2-3 Cream is sold in the U.S. without a prescription. There was no inspection. FDA found the product combines three numbing ingredients and is marketed for cosmetic procedures, which falls outside the over-the-counter rules for external pain-relief drugs.
What FDA found
The cream is a new drug sold without an FDA-approved application.
Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)It mixes three "-caine" numbing ingredients in one product, which the over-the-counter monograph for external pain-relief drugs does not allow.
Section 505G of the FD&C Act; OTC Monograph M017Its labeling claims uses beyond what the monograph permits, such as laser hair removal and tattoo removal.
M017.50(b)The product is misbranded because it is a nonprescription drug that does not meet section 505G requirements and has no approved application.
Section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)Shipping a misbranded drug across state lines is prohibited.
Section 301(a) of the FD&C Act, 21 U.S.C. 331(a)
What FDA wants
FDA asks the company to write within fifteen working days describing the specific steps taken to correct the violations and prevent them from recurring, with supporting documents. If corrections cannot be finished in that time, the company must say why and give a completion date.
Who should pay attention
- med spas and cosmetic procedure providers who use or resell numbing creams
- distributors and online retailers selling over-the-counter topical anesthetics
- companies combining multiple active ingredients in OTC drug products
This is a summary. Read the original letter on fda.gov.